


ARYLOXYCYCLOALKENYL-
AND ARYLOXYIMINOCYCLOALKENYLHYDROXYUREAS

ABSTRACT

The present invention provides a compound of formula (I):



(I)

5 wherein Ar is (a) phenyl, naphthyl and biphenyl, each optionally substituted with C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, C_{2-4} alkoxyalkoxy, C_{1-4} alkylthio, hydroxy, halo, cyano, amino, C_{1-4} alkylamino, di (C_{2-4}) alkylamino, C_{2-6} alkanoylamino, carboxy, C_{2-6} alkoxy carbonyl, or optionally substituted phenyl, phenoxy, phenylthio or phenylsulfinyl or (b) furyl, benzo[b]furyl,
10 thienyl, benzo[b]thienyl, pyridyl or quinolyl, each optionally substituted with C_{1-4} alkyl, C_{1-4} haloalkyl, halo, C_{1-4} alkoxy, optionally-substituted phenyl, phenoxy or phenylthio, X is $\text{C}_1\text{-C}_4$ alkylene, $\text{C}_2\text{-C}_4$ alkenylene, $-(\text{CHR}^1)_m\text{-Q}^1\text{-(CHR}^2)_n\text{-}$, $-\text{O-(CHR}^1)_j\text{-Q}^2\text{-}$ and $-(\text{CHR}^1)\text{-O-N=}$ in which the N= moiety is attached to the cycloalkene ring; and in which Q^1 is O, S, SO, SO_2 , NR^3 , CH=N-O or CO, Q^2 is
15 O, S, SO, SO_2 or NR^3 , and R^1 , R^2 and R^3 are each hydrogen or $\text{C}_1\text{-C}_4$ alkyl, m and n are each an integer from 0 to 4 and j is an integer from 1 to 4; p is an integer of 1 or 2; Y is hydrogen, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{2-4} alkoxyalkyl, C_{1-4} alkylthio, hydroxy, halo, cyano or amino; Z is hydrogen or C_{1-4} alkyl; and M is hydrogen, a pharmaceutically acceptable cation or a pharmaceutically acceptable
20 metabolically cleavable group.

Further the invention provides a pharmaceutical composition for treating a medical condition for which a 5-lipoxygenase inhibitor is needed in a mammalian subject which comprises a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. Preferably the medical condition
25 is an inflammatory disease, allergy or cardiovascular diseases.